216 related articles for article (PubMed ID: 35612854)
1. Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.
Teoh D; Nam G; Aase DA; Russell R; Melton GB; Kulasingam S; Vogel RI
JAMA Netw Open; 2022 May; 5(5):e2214020. PubMed ID: 35612854
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
4. Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
Lei J; Ploner A; Lehtinen M; Sparén P; Dillner J; Elfström KM
Br J Cancer; 2020 Jul; 123(1):155-160. PubMed ID: 32362659
[TBL] [Abstract][Full Text] [Related]
5. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of primary HPV screening cut-off for colposcopy referrals in HPV-vaccinated cohort: Observational study.
Beecroft M; Gurumurthy M; Cruickshank ME
BJOG; 2023 Jan; 130(2):210-213. PubMed ID: 36054732
[TBL] [Abstract][Full Text] [Related]
7. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
8. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
9. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
11. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
12. HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study.
Palmer TJ; McFadden M; Pollock KG; Kavanagh K; Cuschieri K; Cruickshank M; Cotton S; Nicoll S; Robertson C
Br J Cancer; 2016 Mar; 114(5):582-9. PubMed ID: 26931370
[TBL] [Abstract][Full Text] [Related]
13. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
14. Performance of high-risk human papillomavirus testing in the triage of abnormal cervical cytology among Chinese younger women in Shanghai, China.
Jiang L; Zeng Y; Li J; Wang H; Xia Y; Fang X; Zhang P
Asian Pac J Cancer Prev; 2011; 12(11):2963-7. PubMed ID: 22393972
[TBL] [Abstract][Full Text] [Related]
15. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
16. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
19. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results.
Castle PE; Xie X; Xue X; Poitras NE; Lorey TS; Kinney WK; Wentzensen N; Strickler HD; Burger EA; Schiffman M
Prev Med; 2019 Jan; 118():44-50. PubMed ID: 30316878
[TBL] [Abstract][Full Text] [Related]
20. Risk of progression of cervical intraepithelial neoplasia grade 2 in human papillomavirus-vaccinated and unvaccinated women: a population-based cohort study.
Krog L; Lycke KD; Kahlert J; Randrup TH; Jensen PT; Rositch AF; Hammer A
Am J Obstet Gynecol; 2024 Apr; 230(4):430.e1-430.e11. PubMed ID: 38569830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
